Table 1.
Preoperative, operative and postoperative data of the patients included in the study (n = 141).
| Variable | Total Series (n = 149) |
With Stricture (n = 21) |
W/o Stricture (n = 128) |
p-Value |
|---|---|---|---|---|
| Preoperative data | ||||
| Age, years, median (IQR) | 70 (7) | 69 (8) | 70 (7) | 0.99 |
| Body mass index, median (IQR, range) | 26.6 (4.8) | 27 (4.1) | 26.3 (4.8) | 0.496 |
| ASA score I, n (%) | 27 (18.1) | 4 (19) | 23 (18) | 0.939 |
| ASA score II, n (%) | 97 (65.1) | 13 (61,9) | 84 (65.6) | |
| ASA score III, n (%) | 25 (16.8) | 4 (19) | 21 (16.4) | |
| Charlson comorbidity index, median (IQR) | 4 (2) | 4 (2) | 4 (2) | 0.619 |
| Previous urethral sling surgery, n (%) | 12 (8.8) | 2 (9.5) | 10 (7.8) | 0.789 |
| Previous radiation, n (%) | 21 (14.9) | 9 (42.9) | 12 (9.4) | <0.0001 |
| Androgen deprivation, n (%) | 9 (6) | 5 (23.8) | 4 (3.1) | 0.003 |
| D’Amico low risk group, n (%) | 16 (10.7) | 2 (9.5) | 14 (10.9) | 0.319 |
| D’Amico intermediate risk group, n (%) | 32 (21.5) | 2 (9.5) | 30 (23.5) | |
| D’Amico high risk group, n (%) | 101 (67.8) | 17 (81) | 84 (65.6) | |
| Months since prostatectomy, median (IQR) | 48 (41) | 72 (38) | 47 (40) | 0.012 |
| 24-h pad count (PPD), n, median (IQR) | 5 (3) | 6 (1) | 4 (3) | <0.0001 |
| 24-h pad test, mL, median (IQR) | 500 (460) | 950 (550) | 455 (425) | <0.0001 |
| ICIQ-SF total, median (IQR, range) | 15 (5) | 19 (5) | 14 (5) | <0.0001 |
| ICIQ-SF Question 1 | 4 (0) | 5 (1) | 4 (0) | <0.0001 |
| ICIQ-SF Question 2 | 4 (2) | 6 (2) | 4 (2) | 0.001 |
| ICIQ-SF Question 3 | 6 (3) | 8 (2) | 6 (3) | <0.0001 |
| Operative data | ||||
| Operative time, min, median (IQR) | 55 (22) | 60 (25) | 55 (20) | 0.44 |
| Perioperative complication, n (%) | 2 (1.3) | 0 (0) | 2 (1.6) | 1 |
| VAS for pain (0–10), median (IQR) (1) | 0 (1) | 1 (2) | 0 (1) | 0.093 |
| Postoperative data | ||||
| Postoperative complications (2), any grade, n (%) | 31 (22) | 6 (28.6) | 25 (19.5) | 0.46 |
| Grade I (2), n (%) | 23 (16.3) | 4 (19) | 19 (14.8) | |
| Grade II (2), n (%) | 2 (1.4) | 1 (4.8) | 1 (0.8) | |
| Grade III (2), n (%) | 6 (4.3) | 1 (4.8) | 5 (3.9) | |
| Surgical revision, n (%) | 9 (6) | 2 (9.5) | 7 (5.8) | 0.47 |
| Device explant, n (%) | 7 (4.7) | 2 (9.5) | 5 (3.9) | 0.26 |
| De novo OAB symptoms, n (%) | 6 (4) | 1 (4.8) | 5 (3.9) | 0.85 |
| Total filling volume, mL, median (IQR) | 15 (8) | 17 (5.5) | 14.5 (7) | 0.006 |
| Number of fillings, median (IQR) | 1 (3) | 3 (1) | 1 (2) | <0.0001 |
| Patients with pad test ≤ 20 mL, n (%) | 114 (76.5) | 8 (38) | 106 (82.8) | <0.0001 |
| 24-h pad count (PPD) (1), n, median (IQR) | 0 (1) | 1 (2) | 0 (0) | <0.0001 |
| 24-h pad test, mL, median (IQR) | 0 (15) | 70 (180) | 0 (10) | <0.0001 |
| PGI-I = 1 (very much better), n (%) | 104 (69.8) | 10 (47.6) | 94 (73.4) | 0.006 |
| PGI-I = 2 (much better), n (%) | 26 (17.5) | 4 (19) | 22 (17.2) | |
| PGI-I = 3 (better), n (%) | 13 (8.7) | 5 (23.8) | 8 (6.2) | |
| PGI-I = 4 (same), n (%) | 5 (3.4) | 1 (4.8) | 4 (3.1) | |
| PGI-I = 5 (worse), n (%) | 1 (0.7) | 1 (4.8) | 0 (0) |
(1) Pain evaluated at discharge, usually on day 1 after surgery. (2) According to Clavien–Dindo classification. IQR, Interquartile range; ASA, American Society of Anesthesiologists; PPD, pads per day; ICIQ-SF, International Consultation on Incontinence Questionnaire-Short Form; VAS, Visual Analog Scale; OAB, overactive bladder; PGI-I, Patient Global Impression of Improvement.